Analyst
Jones Trading
Equibles does not estimate personal net worth.
Justin Walsh is recorded as Analyst at Jones Trading. Justin Walsh has spoken on 9 earnings calls across 6 companies, most recently for Volitionrx Ltd on August 14, 2026. Those appearances were for Volitionrx Ltd (VNRX), RenovoRx, Inc. (RNXT), TriSalus Life Sciences, Inc. (TLSI), NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC), Achieve Life Sciences, Inc. (ACHV) and 1 other company. The companies whose calls Justin Walsh spoke on are classified in the Healthcare sector.
“It would be great if you could provide some additional color on the reimbursement approval process relevant to NUCU lung cancer in France.”
“I was wondering if you could provide some additional color on how you view the stereo CED opportunity. Do you think it's meaningful when used with drugs in the development stage, or do you think it has to be adopted as a standard for an approved agent?”
“I was wondering if you could provide additional color on what prompted the physician to use TAMP and RenovoCast in that particular sarcoma patient.”
“I think you alluded to this a little bit in your last answer with the reimbursement, But I'm wondering if you could remind us where there's overlap in call points for the current liver market and the adjacent markets that you're working to expand into.”
“I was curious if you could expand on the potential clinical utility of new QNets in HS. I'm wondering how physicians might use the additional information to inform treatment decisions.”
Jones Trading
Analyst
Transcript header (unverified)
VNRX
Medical Devices · Healthcare
RNXT
Biotechnology · Healthcare
XAIR
Medical Devices · Healthcare
